NO116869B - - Google Patents
Download PDFInfo
- Publication number
- NO116869B NO116869B NO16118766A NO16118766A NO116869B NO 116869 B NO116869 B NO 116869B NO 16118766 A NO16118766 A NO 16118766A NO 16118766 A NO16118766 A NO 16118766A NO 116869 B NO116869 B NO 116869B
- Authority
- NO
- Norway
- Prior art keywords
- cell
- cells
- antigen
- pertussis
- extract
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 claims description 40
- 239000000427 antigen Substances 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 18
- 210000002421 cell wall Anatomy 0.000 claims description 14
- 201000005702 Pertussis Diseases 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 9
- 241000588832 Bordetella pertussis Species 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 230000009172 bursting Effects 0.000 claims description 5
- 210000000805 cytoplasm Anatomy 0.000 claims description 5
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 101710194807 Protective antigen Proteins 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000002609 medium Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229940031348 multivalent vaccine Drugs 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 235000021053 average weight gain Nutrition 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010032972 Cellfood Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000220221 Rosales Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 235000011126 aluminium potassium sulphate Nutrition 0.000 description 1
- 229940009859 aluminum phosphate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- -1 benzyl- Chemical group 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229940050271 potassium alum Drugs 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- ALNUHUMOGUVHIO-XXJNWDAFSA-M sodium;7-[(1r,2s)-2-hexyl-5-hydroxycyclopentyl]heptanoate Chemical compound [Na+].CCCCCC[C@H]1CCC(O)[C@@H]1CCCCCCC([O-])=O ALNUHUMOGUVHIO-XXJNWDAFSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42669165A | 1965-01-19 | 1965-01-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO116869B true NO116869B (OSRAM) | 1969-06-02 |
Family
ID=23691819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO16118766A NO116869B (OSRAM) | 1965-01-19 | 1966-01-10 |
Country Status (11)
| Country | Link |
|---|---|
| BE (1) | BE675310A (OSRAM) |
| BR (1) | BR6676474D0 (OSRAM) |
| DE (1) | DE1617605C3 (OSRAM) |
| DK (1) | DK115720B (OSRAM) |
| ES (1) | ES322331A1 (OSRAM) |
| FR (2) | FR1475742A (OSRAM) |
| GB (1) | GB1119543A (OSRAM) |
| IL (1) | IL24946A (OSRAM) |
| NL (1) | NL6600703A (OSRAM) |
| NO (1) | NO116869B (OSRAM) |
| SE (1) | SE326797B (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ188211A (en) * | 1977-10-28 | 1984-09-28 | American Cyanamid Co | Isolation of polyribosyl ribitol phosphate(prp)from haemophilus influenzae type b;vaccine comprising prp and bordetellapertussis antigens |
| US4338299A (en) * | 1980-11-17 | 1982-07-06 | Dso "Pharmachim" | Vaccine against pertussis |
| US4474758A (en) * | 1981-11-19 | 1984-10-02 | American Cyanamid Company | Haemophilus influenzae type b and pertussis outer membrane component combined vaccine |
| EP0986315A4 (en) * | 1997-06-04 | 2001-05-02 | Improvements Ltd Cellular | METHOD AND DEVICE FOR DISSOLVING THE BIOLOGICAL MATERIAL |
-
1966
- 1966-01-10 IL IL2494666A patent/IL24946A/en unknown
- 1966-01-10 NO NO16118766A patent/NO116869B/no unknown
- 1966-01-12 GB GB150466A patent/GB1119543A/en not_active Expired
- 1966-01-17 BR BR17647466A patent/BR6676474D0/pt unknown
- 1966-01-18 SE SE00630/66A patent/SE326797B/xx unknown
- 1966-01-18 DE DE19661617605 patent/DE1617605C3/de not_active Expired
- 1966-01-18 FR FR46281A patent/FR1475742A/fr not_active Expired
- 1966-01-18 DK DK26066A patent/DK115720B/da unknown
- 1966-01-18 ES ES0322331A patent/ES322331A1/es not_active Expired
- 1966-01-19 NL NL6600703A patent/NL6600703A/xx unknown
- 1966-01-19 BE BE675310D patent/BE675310A/xx unknown
- 1966-04-15 FR FR57878A patent/FR5550M/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE1617605C3 (de) | 1974-08-29 |
| FR1475742A (fr) | 1967-04-07 |
| DE1617605A1 (de) | 1971-04-01 |
| ES322331A1 (es) | 1966-11-16 |
| NL6600703A (OSRAM) | 1966-07-20 |
| SE326797B (OSRAM) | 1970-08-03 |
| BR6676474D0 (pt) | 1973-09-11 |
| FR5550M (OSRAM) | 1967-11-20 |
| GB1119543A (en) | 1968-07-10 |
| BE675310A (OSRAM) | 1966-07-19 |
| IL24946A (en) | 1969-05-28 |
| DE1617605B2 (de) | 1974-01-31 |
| DK115720B (da) | 1969-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Erkmen | Inactivation of Salmonella typhimurium by high pressure carbon dioxide | |
| JP3107568B2 (ja) | ブドウ膜炎の処置 | |
| EP0020356A1 (en) | PASTEURELLOSIS VACCINES. | |
| US20140004178A1 (en) | Omv vaccine against burkholderia infections | |
| US3395219A (en) | Process for production of pertussis antigen | |
| NO179360B (no) | Fremgangsmåte for fremstilling av en fiskevaksine samt en ikke-virulent, inntrengende mutant bakteriestamme inneholdt i vaksinen | |
| Demazeau et al. | High hydrostatic pressure and biology: a brief history | |
| NO116869B (OSRAM) | ||
| WO1993021951A1 (en) | Method for producing a bacterial vaccine and novel vaccines produced thereby | |
| Foster et al. | Immunological role of Brucella abortus cell walls | |
| Kishimoto et al. | Electron microscopic study on the interaction between normal guinea pig peritoneal macrophages and Coxiella burnetii | |
| NO117986B (OSRAM) | ||
| NO116870B (OSRAM) | ||
| US3141824A (en) | Pertussis antigen | |
| CN102746414B (zh) | 一种细菌脂多糖的沉降方法 | |
| CN106434570B (zh) | 一种狂犬病病毒裂解液及其应用 | |
| US2965543A (en) | Alcohol detoxification of pertussis vaccines | |
| McGHEE et al. | Osmotically sensitive Brucella in infected normal and immune macrophages | |
| RU2709657C2 (ru) | Способ лиофильного высушивания аттенуированных бактерий B. pertussis, аттенуированная бактерия B. pertussis, штамм аттенуированных бактерий B. Pertussis, вакцина, лиофилизированный вакцинный препарат | |
| NO141565B (no) | Fremgangsmaate for fremstilling av en vaksine mot klovsyke | |
| NO823124L (no) | Fremgangsmaate for fremstilling av en vaksine mot vibrio anguillarum. | |
| US20250049907A1 (en) | Brucella canis vaccine for dogs | |
| WO2019079716A1 (en) | VACCINE AGAINST BRUCELLA CANIS FOR DOGS | |
| Idziak et al. | Effect of pH on the pathogenic functions of Salmonella typhimurium | |
| WO2024102751A2 (en) | Lyophilized and stabilized live attenuated formulated vaccine against tularemia |